Pfizer partners with YaoPharma for weight management treatment
Pfizer said on Tuesday it had entered into an exclusive licensing agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical, for the development and commercialization of an experimental weight management treatment.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments